Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Kidney Neoplasms"" wg kryterium: Temat


Tytuł:
A dynamic visualization clinical tool constructed and validated based on the SEER database for screening the optimal surgical candidates for bone metastasis in primary kidney cancer.
Autorzy:
Jiang L; Department of Orthopedics, The China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun, 130033, Jilin, People's Republic of China.
Tong Y; Department of Orthopedics, The China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun, 130033, Jilin, People's Republic of China.
Wang J; Department of Orthopedics, Rizhao People's Hospital, Rizhao, 276800, Shandong, People's Republic of China.
Jiang J; Department of Orthopedics, The China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun, 130033, Jilin, People's Republic of China.
Gong Y; Department of Orthopedics, The China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun, 130033, Jilin, People's Republic of China.
Zhu D; Department of Orthopedics, The China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun, 130033, Jilin, People's Republic of China.
Zheng L; Department of Orthopedics, The China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun, 130033, Jilin, People's Republic of China.
Zhao D; Department of Orthopedics, The China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun, 130033, Jilin, People's Republic of China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 12; Vol. 14 (1), pp. 3561. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Neoplasms*/surgery
Kidney Neoplasms*/surgery
Humans ; Early Detection of Cancer ; Area Under Curve ; Nomograms ; Propensity Score ; SEER Program ; Prognosis
Czasopismo naukowe
Tytuł:
Urinary cancer detection by the target urine volatile organic compounds biosensor platform.
Autorzy:
Suthat Na Ayutaya V; School of Internal Medicine, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand.
Tantisatirapoon C; School of Surgery, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand.
Aekgawong S; School of Surgery, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand.
Anakkamatee W; Department of Mathematics, Faculty of Science, Naresuan University, Phitsanulok, Thailand.
Danjittrong T; Department of Anesthesiology, Chulabhorn Hospital, Bangkok, Thailand.
Kreepala C; School of Internal Medicine, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 12; Vol. 14 (1), pp. 3551. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Journal Article
MeSH Terms:
Volatile Organic Compounds*/analysis
Carcinoma, Renal Cell*
Kidney Neoplasms*
Male ; Humans ; Butanes ; Ethanol ; Hydrogen ; Methane ; Oxides
Czasopismo naukowe
Tytuł:
Analysis of progression after elective distal ureterectomy and effects of salvage radical nephroureterectomy in patients with distal ureteral urothelial carcinoma.
Autorzy:
Lee CU; Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Gyeonggi-do, Republic of Korea.
Lee JH; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Lee HW; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Chung JH; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Song W; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Kang M; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Jeon HG; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Jeong BC; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Seo SI; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Jeon SS; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Sung HH; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 12; Vol. 14 (1), pp. 3497. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Journal Article
MeSH Terms:
Ureter*/surgery
Ureter*/pathology
Ureteral Neoplasms*
Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*/surgery
Kidney Neoplasms*/pathology
Humans ; Nephroureterectomy ; Nephrectomy ; Disease Progression ; Retrospective Studies ; Neoplasm Recurrence, Local/surgery
Czasopismo naukowe
Tytuł:
Pan-cancer analysis reveals potential immunological and prognostic roles of METTL7A in human cancers.
Autorzy:
Wang B; Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jiang J; Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Luo D; Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. .
Wang X; Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 12; Vol. 14 (1), pp. 3476. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/diagnosis
Kidney Neoplasms*/diagnosis
Methyltransferases*/genetics
Methyltransferases*/metabolism
Prostatic Neoplasms*/diagnosis
Humans ; Male ; Prognosis
Czasopismo naukowe
Tytuł:
Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.
Autorzy:
Kosumi T; Kyushukouseikai Clinic, 1-2-12 Tenjin, Chuo-Ku, Fukuoka-Shi, 810-0001, Japan. .
Kobayashi M; Okazakiyuuai Clinic, 104-1 Azaikeda, Tsutsubaricho, Okazaki-Shi, Aichi-ken, 444-0932, Japan.
Shimodaira S; Department of Regenerative Medicine, Kanazawa Medical University, Kahoku, Ishikawa, 920-0293, Japan.
Sugiyama H; Department of Cancer Immunology, Osaka University Graduate School of Medicine, Suita-City, Osaka, 565-0871, Japan.
Koido S; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kashiwa Hospital, The Jikei University School of Medicine, 163-1 Kashiwa-Shita, Kashiwa, Chiba, 277-8567, Japan.
Pokaż więcej
Źródło:
Journal of medical case reports [J Med Case Rep] 2024 Feb 10; Vol. 18 (1), pp. 88. Date of Electronic Publication: 2024 Feb 10.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Adenocarcinoma of Lung*/drug therapy
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Wilms Tumor*
Kidney Neoplasms*/drug therapy
Vaccines*/therapeutic use
Female ; Humans ; Middle Aged ; Erlotinib Hydrochloride/therapeutic use ; Mucin-1/genetics ; Mucin-1/therapeutic use ; WT1 Proteins/genetics ; WT1 Proteins/therapeutic use ; ErbB Receptors/genetics ; ErbB Receptors/therapeutic use ; Vaccination ; Dendritic Cells ; Mutation ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Correlations of SDF-1ɑ and XRCC1 gene polymorphisms with the risk of renal cancer development and bioinformatics studies of SDF-1α and XRCC1 and the prognosis of renal cancer.
Autorzy:
Zhang W; School of Public Health, Inner Mongolia Medical University, Hohhot, China.
Su Y; School of Public Health, Inner Mongolia Medical University, Hohhot, China.
Yue G; Department of Urology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Zhao L; School of Public Health, Inner Mongolia Medical University, Hohhot, China.; Key Laboratory of Molecular Epidemiology of Chronic Diseases, Inner Mongolia Medical University, Hohhot, China.
Li H; School of Public Health, Inner Mongolia Medical University, Hohhot, China.; Key Laboratory of Molecular Epidemiology of Chronic Diseases, Inner Mongolia Medical University, Hohhot, China.
Jia M; School of Public Health, Inner Mongolia Medical University, Hohhot, China.
Wang Y; School of Public Health, Inner Mongolia Medical University, Hohhot, China.
Liu D; School of Public Health, Inner Mongolia Medical University, Hohhot, China.
Wang H; School of Public Health, Inner Mongolia Medical University, Hohhot, China. .; Department of Biochemistry and Molecular Biology, School of Basic Medicine, Inner Mongolia Medical University, Hohhot, China. .
Gao Y; School of Public Health, Inner Mongolia Medical University, Hohhot, China. .; Key Laboratory of Molecular Epidemiology of Chronic Diseases, Inner Mongolia Medical University, Hohhot, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 09; Vol. 14 (1), pp. 3367. Date of Electronic Publication: 2024 Feb 09.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/genetics
Kidney Neoplasms*/genetics
Humans ; DNA-Binding Proteins/genetics ; Chemokine CXCL12/genetics ; Genetic Predisposition to Disease ; X-ray Repair Cross Complementing Protein 1/genetics ; Polymorphism, Single Nucleotide ; Genotype ; Prognosis ; Computational Biology ; Case-Control Studies
Czasopismo naukowe
Tytuł:
Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer.
Autorzy:
Musleh Ud Din S; Department of Internal Medicine, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA.
Streit SG; Department of Hematology and Oncology, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA.
Huynh BT; Department of Pharmacy, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA.
Hana C; Department of Hematology and Oncology, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA.
Abraham AN; Department of Hematology and Oncology, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA.
Hussein A; Department of Hematology and Oncology, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 08; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 08.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Carcinoma, Renal Cell*/metabolism
Kidney Neoplasms*/metabolism
Humans ; Von Hippel-Lindau Tumor Suppressor Protein/genetics ; Vascular Endothelial Growth Factor A/metabolism ; Hypoxia ; Hypoxia-Inducible Factor 1, alpha Subunit/genetics
Czasopismo naukowe
Tytuł:
Neutrophils in the era of single-cell RNA sequencing: functions and targeted therapies in cancer.
Autorzy:
Qin J; National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin 300060, China.; Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
Wei F; National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin 300060, China.; Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
Ren X; National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin 300060, China.; Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.; Department of Biotherapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
Pokaż więcej
Źródło:
Cancer biology & medicine [Cancer Biol Med] 2024 Feb 05; Vol. 20 (12).
Typ publikacji:
Editorial; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Renal Cell*
Kidney Neoplasms*
Humans ; Neutrophils ; Sequence Analysis, RNA
Raport
Tytuł:
CD2AP is a potential prognostic biomarker of renal clear cell carcinoma.
Autorzy:
Chen C; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China.
Xu J; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China.
Zhang JX; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China.
Chen LY; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China.
Wei YA; Department of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhang WM; Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Shao PF; Department of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xu HG; Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (4), pp. e7055.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/genetics
Carcinoma*
Kidney Neoplasms*/genetics
Cytoskeletal Proteins*
Adaptor Proteins, Signal Transducing*
Humans ; DNA Copy Number Variations ; Prognosis ; Biomarkers
Czasopismo naukowe
Tytuł:
Incidence of immunotherapy-related hyperprogressive disease (HPD) across HPD definitions and cancer types in observational studies: A systematic review and meta-analysis.
Autorzy:
Kim MJ; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Hong SPD; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Park Y; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Chae YK; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (3), pp. e6970.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Liver Neoplasms*/etiology
Kidney Neoplasms*/etiology
Humans ; Incidence ; Immunotherapy/adverse effects ; Disease Progression
Czasopismo naukowe
Tytuł:
Low nuclear expression of HIF-hydroxylases PHD2/EGLN1 and PHD3/EGLN3 are associated with poor recurrence-free survival in clear cell renal cell carcinoma.
Autorzy:
Luomala L; Dept. of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Mattila K; Department of Oncology and Radiotherapy, FICAN West Cancer Centre, University of Turku, Turku University Hospital, Turku, Finland.; InFlames Research Flagship, University of Turku, Turku, Finland.
Vainio P; Dept. of Pathology, Turku University Hospital, University of Turku, Turku, Finland.
Nisén H; Dept. of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Pellinen T; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Lohi J; Diagnostic Center, HUSLAB Laboratory Services, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Laajala TD; Diagnostic Center, HUSLAB Laboratory Services, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.; Research Program in Systems Oncology (ONCOSYS) and iCAN - Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.
Järvinen P; Dept. of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Koskenniemi AR; Dept. of Pathology, Turku University Hospital, University of Turku, Turku, Finland.
Jaakkola P; Department of Oncology and Radiotherapy, FICAN West Cancer Centre, University of Turku, Turku University Hospital, Turku, Finland.
Mirtti T; Diagnostic Center, HUSLAB Laboratory Services, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.; Research Program in Systems Oncology (ONCOSYS) and iCAN - Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.; Foundation for the Finnish Cancer Institute, Helsinki, Finland.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (3), pp. e6998.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/pathology
Kidney Neoplasms*/pathology
Humans ; Mixed Function Oxygenases ; Prospective Studies ; Retrospective Studies ; Neoplasm Recurrence, Local ; Hypoxia-Inducible Factor-Proline Dioxygenases ; Hypoxia ; Biomarkers ; Hypoxia-Inducible Factor 1, alpha Subunit
Czasopismo naukowe
Tytuł:
Neighborhood social vulnerability and disparities in time to kidney cancer surgical treatment and survival in Arizona.
Autorzy:
Valencia CI; Department of Family and Community Medicine, College of Medicine - Tucson, The University of Arizona, Tucson, Arizona, USA.
Wightman P; Center for Population Health Sciences, The University of Arizona, Tucson, Arizona, USA.
Morrill KE; Community and Systems Health Science Division, College of Nursing, The University of Arizona, Tucson, Arizona, USA.
Hsu CH; Department of Epidemiology and Biostatistics, The University of Arizona, Tucson, Arizona, USA.
Arif-Tiwari H; Department of Medical Imaging, The University of Arizona, Tucson, Arizona, USA.
Kauffman E; Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Gachupin FC; Department of Family and Community Medicine, College of Medicine - Tucson, The University of Arizona, Tucson, Arizona, USA.
Chipollini J; Department of Urology, The University of Arizona, Tucson, Arizona, USA.
Lee BR; Department of Urology, The University of Arizona, Tucson, Arizona, USA.
Garcia DO; Department of Health Promotion Sciences, The University of Arizona, Tucson, Arizona, USA.
Batai K; Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (3), pp. e7007.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Renal Cell*
Kidney Neoplasms*/surgery
Humans ; Ethnicity ; Arizona/epidemiology ; Social Vulnerability ; Minority Groups ; Kidney
Czasopismo naukowe
Tytuł:
Autorzy:
Ding M; Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, Nanjing, China.
Zhou W; Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing University, Nanjing, China.
Chen W; Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, Nanjing, China.; Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
Mo W; Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, Nanjing, China.; Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
Guo X; Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, Nanjing, China.; Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
Li Y; Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, Nanjing, China.; Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
Ji C; Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, Nanjing, China.
Liu G; Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, Nanjing, China.
Diao W; Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, Nanjing, China.
Guo H; Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, Nanjing, China.
Pokaż więcej
Transliterated Title:
Plasma tsRNAs as novel diagnostic biomarkers for renal cell carcinoma.
Źródło:
Clinical and translational medicine [Clin Transl Med] 2024 Feb; Vol. 14 (2), pp. e1575.
Typ publikacji:
Letter
MeSH Terms:
Carcinoma, Renal Cell*
Kidney Neoplasms*
Humans ; Biomarkers
Opinia redakcyjna
Tytuł:
Clinicopathologic Classification of Renal Cell Carcinoma in Patients ≤40 Years Old From Peru.
Autorzy:
Kamanda S; Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Huanca-Amesquita L; Department of Pathology, National Institute of Neoplastic Diseases, Lima, Peru.
Milla E; Department of Pathology, National Institute of Neoplastic Diseases, Lima, Peru.
Argani P; Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Epstein JI; Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.; Departments of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.; Departments of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Pokaż więcej
Źródło:
International journal of surgical pathology [Int J Surg Pathol] 2024 Feb; Vol. 32 (1), pp. 35-45. Date of Electronic Publication: 2023 Apr 16.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/pathology
Kidney Neoplasms*/pathology
Male ; Female ; Humans ; Adolescent ; Young Adult ; Adult ; Peru/epidemiology ; Translocation, Genetic ; Hematuria
Czasopismo naukowe
Tytuł:
Single-cell analysis reveals ADGRL4+ renal tubule cells as a highly aggressive cell type in clear cell renal cell carcinoma.
Autorzy:
Wang Z; Department of Urology, Qilu Hospital of Shandong University, Jinan, 250012, China.
Zhang Z; Department of Urology, Qilu Hospital (Qingdao), Shandong University, Qingdao, 266035, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Jan 29; Vol. 14 (1), pp. 2407. Date of Electronic Publication: 2024 Jan 29.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/pathology
Kidney Neoplasms*/pathology
Humans ; Kidney/metabolism ; Prognosis ; Single-Cell Analysis ; Nerve Tissue Proteins/metabolism
Czasopismo naukowe
Tytuł:
Immunoinformatics Approach to Design a Chimeric CD70-Peptide Vaccine against Renal Cell Carcinoma.
Autorzy:
Namdari H; Iranian Tissue Bank and Research Center, Tehran University of Medical Science, Tehran, Iran.
Rezaei F; Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Heidarnejad F; Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran.
Yaghoubzad-Maleki M; Division of Biochemistry, Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
Karamigolbaghi M; Iranian Tissue Bank and Research Center, Tehran University of Medical Science, Tehran, Iran.
Pokaż więcej
Źródło:
Journal of immunology research [J Immunol Res] 2024 Jan 27; Vol. 2024, pp. 2875635. Date of Electronic Publication: 2024 Jan 27 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/therapy
Kidney Neoplasms*/therapy
Cancer Vaccines*
Humans ; CD27 Ligand/genetics ; Computational Biology/methods ; Epitopes, B-Lymphocyte ; Epitopes, T-Lymphocyte ; Immunoinformatics ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Protein Subunit Vaccines ; Receptors, Tumor Necrosis Factor
Czasopismo naukowe
Tytuł:
Genetic and clinical characterization of a novel FH founder mutation in families with hereditary leiomyomatosis and renal cell cancer syndrome.
Autorzy:
Sánchez-Heras AB; Cancer Genetic Counselling Unit, Medical Oncology Department, Hospital General Universitario de Elche, 03203, Elche, Alicante, Spain. sanchez_.
Dámaso E; Molecular Genetics Laboratory, Hospital General Universitario de Elche, Elche, Alicante, Spain.; Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), FISABIO-Elche Health Department, Elche, Spain.
Castillejo A; Molecular Genetics Laboratory, Hospital General Universitario de Elche, Elche, Alicante, Spain.; Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), FISABIO-Elche Health Department, Elche, Spain.
Robledo M; Hereditary Endocrine Cancer, Human Cancer Genetics Programme Spanish National Cancer Centre (CNIO), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, 28029, Madrid, Spain.
Teulé A; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona, Spain.
Lázaro C; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona, Spain.
Sánchez-Martínez R; Multidisciplinary Rare Disease Unit, Internal Medicine Department, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
Zúñiga Á; Clinical Genetics Unit, Hospital Politécnico y Universitario La Fe, Valencia, Spain.
López-Fernández A; Hereditary Cancer Genetics Group, VHIO, and Medical Oncology Department, Hospital Vall D'Hebron, Barcelona, Spain.
Balmaña J; Hereditary Cancer Genetics Group, VHIO, and Medical Oncology Department, Hospital Vall D'Hebron, Barcelona, Spain.
Robles L; Medical Oncology Department. Hospital 12 de Octubre, Madrid, Spain.
Ramon Y Cajal T; Familiar Cancer Clinic, Medical Oncology Department, Santa Creu i Sant Pau Hospital, Barcelona, Spain.
Castillejo MI; Molecular Genetics Laboratory, Hospital General Universitario de Elche, Elche, Alicante, Spain.; Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), FISABIO-Elche Health Department, Elche, Spain.
Ibañez RP; Cancer Genetic Counselling Unit, Medical Oncology Department, Hospital General Universitario de Elche, 03203, Elche, Alicante, Spain.
Sevila CM; Cancer Genetic Counselling Unit, Medical Oncology Department, Hospital General Universitario de Elche, 03203, Elche, Alicante, Spain.
Sánchez-Mira A; Molecular Genetics Laboratory, Hospital General Universitario de Elche, Elche, Alicante, Spain.; Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), FISABIO-Elche Health Department, Elche, Spain.
Escandell I; Servicio de Dermatología, Hospital General Universitario de Elda, Elda, Alicante, Spain.
Gómez L; Urology Department, Hospital General Universitario de Elche, Elche, Alicante, Spain.
Berbel P; Departamento de Histología y Anatomía, Facultad de Medicina, Universidad Miguel Hernández, Sant Joan d'Alacant, Alicante, Spain.
Soto JL; Molecular Genetics Laboratory, Hospital General Universitario de Elche, Elche, Alicante, Spain.; Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), FISABIO-Elche Health Department, Elche, Spain.
Pokaż więcej
Źródło:
Orphanet journal of rare diseases [Orphanet J Rare Dis] 2024 Jan 26; Vol. 19 (1), pp. 26. Date of Electronic Publication: 2024 Jan 26.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Renal Cell*
Leiomyomatosis*/genetics
Leiomyomatosis*/pathology
Kidney Neoplasms*/genetics
Skin Neoplasms*/pathology
Neoplastic Syndromes, Hereditary*
Uterine Neoplasms*
Female ; Humans ; Mutation/genetics ; Syndrome
SCR Disease Name:
Hereditary leiomyomatosis and renal cell cancer
Czasopismo naukowe
Tytuł:
HIF-2α/LINC02609/APOL1-mediated lipid storage promotes endoplasmic reticulum homeostasis and regulates tumor progression in clear-cell renal cell carcinoma.
Autorzy:
Xiao H; Department of Urology, Institute of Urology, Anhui Province Key Laboratory of Genitourinary Diseases, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, 230022, China.; Department of Urology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei Province, 430022, China.; Department of Pathogenic Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Qu Y; College of Basic Medicine, Xinxiang Medical University, Xinxiang, Henan, 453000, China.
Li H; Department of Urology, Institute of Urology, Anhui Province Key Laboratory of Genitourinary Diseases, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, 230022, China.
Zhang Y; Department of Urology, Institute of Urology, Anhui Province Key Laboratory of Genitourinary Diseases, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, 230022, China.
Fei M; Department of Urology, Institute of Urology, Anhui Province Key Laboratory of Genitourinary Diseases, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, 230022, China.
Liang C; Department of Urology, Institute of Urology, Anhui Province Key Laboratory of Genitourinary Diseases, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, 230022, China. Liang_.
Yang H; Department of Pathogenic Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. .
Zhang X; Department of Urology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei Province, 430022, China. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Jan 23; Vol. 43 (1), pp. 29. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:
Journal Article
MeSH Terms:
Apolipoprotein L1*/genetics
Basic Helix-Loop-Helix Transcription Factors*/genetics
Carcinoma, Renal Cell*
Kidney Neoplasms*
RNA, Long Noncoding*/genetics
Humans ; Endoplasmic Reticulum ; Homeostasis ; Luciferases ; MicroRNAs ; Animals
Czasopismo naukowe
Tytuł:
Patients with high nuclear grade pT1-ccRCC are more suitable for radical nephrectomy than partial nephrectomy: a multicenter retrospective study using propensity score.
Autorzy:
Xu H; Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Xing Z; Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.; Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Ai K; Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Wang J; Department of Oncology, Hunan Cancer Hospital, Changsha, Hunan, China.
Lv Z; Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Deng H; Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Li K; Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wang Y; Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. .
Li Y; Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. .
Pokaż więcej
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2024 Jan 23; Vol. 22 (1), pp. 24. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/surgery
Carcinoma*
Kidney Neoplasms*/surgery
Humans ; Retrospective Studies ; Propensity Score ; Nephrectomy
Czasopismo naukowe
Tytuł:
[Cost-effectiveness of pharmaceutical smoking cessation intervention in China primary cancer prevention].
Autorzy:
Sun PY; Department of Cancer Prevention and Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Xie YT; Department of Cancer Prevention and Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Qie RR; Department of Cancer Prevention and Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Huang H; Department of Cancer Prevention and Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Hu ZL; Department of Cancer Prevention and Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wu MY; Department of Cancer Prevention and Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yan Q; Department of Cancer Prevention and Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhu CR; Department of Epidemiology and Health Statistics, West China School of Public Health, Sichuan University, West China Fourth Hospital, Sichuan University, Chengdu 610044, China.
Shi JF; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zou KY; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhang YW; Department of Cancer Prevention and Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2024 Jan 23; Vol. 46 (1), pp. 66-75.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Smoking Cessation*
Nasopharyngeal Neoplasms*
Kidney Neoplasms*
Humans ; Cost-Benefit Analysis ; Cost-Effectiveness Analysis ; Varenicline ; China ; Pharmaceutical Preparations
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies